Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults

(Seattle Children's) After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent. Researchers have opened a phase 1 trial, PLAT-04, for children and young adults with relapsed or refractory CD22-positive ALL.
Source: EurekAlert! - Biology - Category: Biology Source Type: news